The benefits of spinal cord stimulation (SCS) for patients with painful diabetic peripheral neuropathy (DPN) have been well described in literature dating back decades. Recent U.S. Food and Drug Administration approvals have helped raise therapy visibility as an option for patients with refractory DPN. The accuracy of analyses is imperative in providing health care providers (HCPs) with the most informative guidance for treating patients with DPN.
Patiëntvoorbeelden m.b.t. vergoeding
- ten laste van verzekeraar
- geen vergoeding door verzekeraar